MBD

About Us

Professional company for 3D cell culture platform specialized in anticancer drug sensitivity and efficacy/toxicity test.

History

MBD History

Introducing the footsteps of MBD's growth through constant innovation and continuous research.

  • 2025
  • Dec CytoGen Japan Signs MOU for "Commercialization of Precision Cancer Medicine in Japan's Healthcare Market"
  • Dec Anti-cancer Drug Sensitivity Test Service, 'OncoSensi Test' Expanded to 33 Hospitals
  • Dec Digital Medical Device (CODRP PhenoSW-RT) Product Registration with the MFDS
  • Nov Participation in Japan's Monstar Project (NCCHE)
  • Oct Successful Completion of Technology Evaluation for IPO
  • Oct Selected for MSS Deep Tech Challenge Project: CTC-Based Cancer Diagnosis and Prognosis Prediction Platform Development (3 years, KRW 3.6 billion)
  • Sep Signed the 20th Investment Agreement of Suwon City’s 8th Administration
  • Aug VC Series C Funding Round (16.5 billion won)
  • Aug Central Bio Co., Ltd. Signs MOU for "Development of a New Drug Candidate Evaluation Platform Utilizing PDO and PDOX"
  • Jun Digital medical device manufacturing license obtained (MFDS)
  • Apr Presidential Commendation Awarded in the Science and Technology Promotion Sector by the Ministry of Science and ICT
  • Apr Technology License-out Agreement with Kiyatec in the United States
  • 2024
  • Dec Selected for Ministry of Health and Welfare’s "Korean ARPA-H Project" (4.6 years, 11 billion won)

    ㆍ Development of a high-throughput, large-scale human immune microphysiological system for personalized immunotoxicity assessment

  • Nov Obtained CLIA certification for the CODRP platform to support U.S. commercialization
  • Nov Developed an in vitro–in silico integrated alternative nanotoxicity testing method for regulatory compliance

    ㆍpublished on the Korea Institute of Toxicology (KIT) website (Feb 2025)

  • Aug Initiated investigator-initiated clinical studies to establish the clinical stability and efficacy of the CODRP platform for new cancer indications

    ㆍProstate cancer (chemotherapy): Ajou University Hospital (from August)

    ㆍLung cancer (immunotherapy): Seoul St. Mary’s Hospital, Samsung Medical Center (from September)

  • Jul Established a joint research laboratory with the Charité Comprehensive Cancer Center (Germany)
  • Jun Developed drug and radiation sensitivity prediction models in preparation for 2025 service launch

    ㆍDrug sensitivity models: Gastric cancer (June), Ovarian cancer (October)

    ㆍRadiation sensitivity model: Oral cancer (September)

  • MayContracted Anti-cancer Drug Sensitivity Test Service, 'OncoSensi Test' (Lung cancer) with Yeouido St. Mary's Hospital
  • MayContracted Anti-cancer Drug Sensitivity Test Service 'OncoSensi Test' (Ovarian Cancer) with Samsung Medical Center
  • AprSelected as an Alternative Animal Technology Project by Korea, Ministry of Food and Drug Safety
  • MarContracted Anti-cancer Drug Sensitivity Test Service, OncoSensi Test' (Lung cancer) with Seoul St. Mary's Hospital
  • JauApproval for Lung Cancer Reagent Kit (Grade 1 declaration)
  • 2023
  • DecISO Certification 14001(environment), 37301(compliance with standards), 45001(Safety and Health), and 27001(Information Protection)
  • DecExport of ASFA Spotters to Luxembourg Institute of Health (LIH) and Vanderbilt University Medical Center (US)
  • DecClinical Trials for Products Approval in Ovarian Cancer and Head & neck Cancer (Korea, Ministry of Food and Drug Safety)
  • NovAwarded for Distinguished Service in Research Industry (Korea, Minister of Science and ICT)
  • NovRegistration of FDA Class I and US Medical Device Standard Code for ASFA Spotter V6.5 and ASFA Scanner V5.5
  • JulCertification for Medical Service using "Multiple factor-based anti-cancer drug sensitivity test" (Korea, Health Insurance Review and Assessment Service)
  • MaySelected as Korea Medical Device Development Fund Top 10 Project in 2023 (Head and Neck Cancer)
  • MaySigned MOU with JW C&C New Drug Research Institute to develop innovative anticancer drugs using "cancer organoid diagnosis platform“
  • AprSelected as a Clinical Trial Project by Korea Medical Device Development Fund for Head & Neck Cancer Radiosensitivity Test (2.6 years, 2.3 Billion Won)
  • 2022
  • DecWinner of Innoviz Technology Cooperation Outstanding Company / Medical Device Industry Development Merit Award
  • NovGyeonggi-do Province's promising small and medium-sized enterprises / Small Business Management Innovation Award
  • SepObtained GMP(Good manufacturing practices) certification
  • AugSigned clinical contract to validate solutions for prognosis/prediction of personalized cancer treatment(GC Labs)
  • JulReceived the Bio grand prize at KOREA Leading Company awards (4th consecutive years)
  • MaySelected as a future leading research equipment business (Ministry of Science and ICT, 3.9 years, 7.64 billion won)(Organized)
  • Mar Certification of excellent job invention compensation companies
  • MarConfirmation and equivalence assessment for ‘ATP-Based Chemotherapy Response Assay’ (Health Insurance Review and Assessment Service)
  • 2021
  • DecAwarded the 2021 Venture Award(the corporate sector, the Minister of SMEs and Startups)
  • NovTechnology innovation-oriented SMEs(Inno-Biz) Certification(the Ministry of SMEs and Startups)
  • Oct"3 dimension cancer drug sensitivity" service(Health Insurance Review & Assessment Service)
  • OctSelected as an international joint technology development project in 2021 years (Ministry of Trade, Industry and Energy, 3 years)
  • SepKOREA Bio-Leading Company Grand prize(3 consecutive years)
  • MarObtained CE certification(EC Declaration of Conformity, Phenotrack BCA)
  • FebIPO representative organizer contract
  • FebVC series B investment attraction (11.5 billion won)
  • 2020
  • DecEstablished a joint lab at Luxembourg Institute of Health (LIH)
  • DecSelected as an advanced technology center institute in 2020 (Ministry of Science and ICT)
  • DecSelected as a strategic start-up task(breast cancer) (Ministry of SMEs and Startups)
  • SepSelected as a whole-cycle medical device research and development project(head and neck cancer/ovarian cancer) by Pan-government
  • AugKOREA Bio-Leading Company Grand prize(2 consecutive years)
  • JulSelected as a radiation high-value new material development project(Ministry of Science and ICT)
  • JunObtained KFDA Medical device certification(Calcein AM Kit)
  • MaySelected as a 2020 technology commercialization capability enhancement project (Ministry of Science and ICT)
  • FebJoint development contract for rare cancer treatment based on AI Model (Azothbio)
  • 2019
  • DecAwarded Small and Medium Business excellence Partner Award (Korea Basic Science Institute)
  • DecObtained IVD CE certification approval (ASFAⓇ Scanner)
  • NovObtained ISO 13485 certification
  • SepGrand prize awarded as 2019 Korea Biology leading company
  • SepObtained FDA medical device certification (ASFAⓇ Spotter)
  • JunAttend NIH Spring Exhibit 2019 (USA, Bethesda) Display/PR
  • JunObtained FDA medical device certification (ASFAⓇ Scanner)
  • MaySelected as a start-up leap package business (Ministry of Health and Welfare)
  • AprKFDA medical device manufacture and certification approval (ASFAⓇ Scanner)
  • FebSelected as an investment-related project for public technology transfer company (Ministry of Science and ICT)
  • JanAttracting VC Series A investment (10 Billion won)
  • 2018
  • DecSet-up liver cancer patient personalized drug screening platform for the Precision medicine (Singapore)
  • SepKsilink-LIH- MBD research collaboration agreement for personalized cancer drug screening
  • JunSelected as a business growth technology development business (Ministry of SMEs and Startups)
  • FebSLAS exhibition (USA, San Diego) Display /PR
  • 2017
  • OctSelected for military substitute service designated company(Military Manpower Administration)
  • SepSelected as pharmaceutical biotechnology advanced technology business (Gyeonggido Business & Science Accelerator)
  • SepSelected for industry-academic cooperation technology development project (Ministry of SMEs and Startups)
  • JunAttracting VC seeding investment (2 Billion won)
  • FebVenture capital certification
  • JanSinged sales representative agreement with ThermoFisher Scientific
  • JanSelected as KRISS family corporation and technology leading hidden champion training project (Korea Research Institute of Standards and Science)
  • 2016
  • DecSelected as KBSI family corporation (Korea Basic Science Institute)
  • OctFrance Ksilink, Export 3D cell culture /drug screening device (First)
  • 2015
  • JanEstablished MBD Co., Ltd.
MBD Co., Ltd. | Address : B-8F, 9F 145, Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea
C.E.O : Bo Sung Ku Tel : +82-31-888-9500 Fax : +82-31-888-9981

Copyright © 2021 MBD www.mbdbiotech.com All Rights Reserved.

개인정보보호정책

×
내용이 나옵니다.

이용안내

×
내용이 나옵니다.